Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
A deal that would have brought Seattle Genetics Inc. a second antibody-drug conjugate alongside its Adcetris (brentuximab vedotin) instead...